Results 151 to 160 of about 1,440 (183)

Social Media and Internet Resources for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Current Hematologic Malignancy Reports, 2016
The incorporation of Internet resources and the use of social media among patients, clinicians, advocates, and researchers in the field of hematology and oncology are growing in importance.
Andrew Lane, Vikas Gupta, Naveen Pemmaraju   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Promising results with tagraxofusp in BPDCN

Lancet Oncology, The, 2019
Elizabeth Gourd
exaly   +3 more sources

Evaluating tagraxofusp for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN)

Expert Opinion on Pharmacotherapy, 2022
Unique among hematologic malignancies, blastic plasmacytoid dendritic cell neoplasm (BPDCN) affects multiple compartments including bone marrow, hematologic, lymphatic, dermatologic, and central nervous systems (CNS). Treating BPDCN is challenging, historically, as patients display refractoriness to chemotherapy and absence of long-term remissions in ...
Naveen Pemmaraju, Nathaniel Wilson
exaly   +3 more sources

Managing BPDCN in the context of severe hyperbilirubinemia: a case study

Leukemia and Lymphoma
Francisco Vega, Naveen Pemmaraju, Hagop Kantarjian   +2 more
exaly   +3 more sources

Biological Description of 109 Cases of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) from the French Network of BPDCN

Blood, 2015
Abstract Blastic plasmacytoid dendritic cell neoplasm is a clonal disease derived from precursors of plasmacytoid dendritic cells (pDC). It is a rare neoplasm involving the skin which may or may not be associated from the outset with a leukemic component.
Poret, Eve, Delettre, Fanny Angelot, Biichle, Sabeha, Roogy, Anne, Benazet, Louis, Pagadoy, Maider, Vidal, Chrystelle, Leroux, Franck, Harriverl, Veronique, Ferrand, Christophe, Salaun, Veronique, Benseddik, Zehaira, Guy, Julien, Jacob, Marie Christine, Roumier, Christophe, Feuillard, Jean, Vila, Liliana, Baseggio, Lucile, Plesa, Adriana, Arnoulet, Christine, Benet, B., Drénou, Bernard, Cannard, Veronique Latger, Béné, Marie-Christine, Ticchioni, Michel, Lusina, Daniel, Bardet, Valerie, Tavernier, Magalie L. E. Garff, Macintyre, Elizabeth, Asnafi, Vahid, Noguera, Maria Elena, Bouyer, Sabrina, Lafon, Carine Lecoq, Roussel, Mikael, Jardin, Fabrice, Solly, Françoise, Campos, Lydia, Galoisy, Anne, Arnaud, Anne, Daliphard, Sylvie, Geneviève, Franck, Lacroix, Romaric, Schillinger, Françoise, Seilles, Estelle, Binda, Delphine, Deconinck, Eric, Saas, Philippe, Ottou, Francine Garnache   +47 more
openaire   +2 more sources

Analysis of First-Year Twitter Metrics of a Rare Disease Community for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN

Current Hematologic Malignancy Reports, 2017
The use of Twitter, one of the most commonly engaged social media platforms in the world, is increasing among the general public. Notably, this trend has also been observed among those involved in the healthcare field. With its ability to readily connect diverse groups of stakeholders in a given area of interest, Twitter has become a focal point for ...
Andrew Lane, Vikas Gupta, Naveen Pemmaraju   +2 more
exaly   +3 more sources

Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Current Hematologic Malignancy Reports, 2019
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, clinically aggressive hematologic malignancy that has heterogeneous presentation and can involve the skin, lymph nodes, and bone marrow. Recent advancements in our patho-biologic understanding of the disease have led to the development of new targeted therapies for BPDCN.
David Rizzieri, Naveen Pemmaraju, Minas Platon Economides   +2 more
exaly   +3 more sources

BPDCN: state of the art

Hematology American Society of Hematology Education Program
Abstract The emergence of blastic plasmacytoid dendritic cell neoplasm (BPDCN) as its own distinct entity within the pantheon of hematologic malignancies is due to the growing understanding of its unique multiorgan clinical presentation and characteristic skin lesions. The occurrence of BPDCN is generally heralded by a multicompartmental
exaly   +3 more sources

Outcomes of CNS involvement in blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Journal of Clinical Oncology, 2021
e19043 Background: BPDCN is rare cancer commonly involving the skin and marrow. Tagraxofusp (Tag), a CD123 targeted therapy, was the first FDA approved drug for BPDCN in 2018. CNS involvement occurs in 10-60% of patients and CNS staging and prophylactic (ppx) practices are variable.
Irl Brian Greenwell, James Davis, Hong Li, Deborah Soong, Justin Taylor, Andrew A. Lane, David Rizzieri   +6 more
openaire   +1 more source

Role of tagraxofusp in treating blastic plasmacytoid dendritic cell neoplasm (BPDCN)

Expert Opinion on Biological Therapy, 2019
Introduction: Advances and drug development in rare diseases, such as blastic plasmacytoid dendritic cell neoplasm (BPDCN), has historically been limited by small numbers of patients in the target population. In recent years, the development of tagraxofusp (SL-401) (ELZONRIS, Stemline Therapeutics) for the treatment of adult and pediatric BPDCN has ...
Mansour Alfayez, Marina Konopleva, Naveen Pemmaraju   +2 more
openaire   +2 more sources